삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 이세훈 교수

진료분야
폐암, 두경부암
진료일정 05 月
날짜
목
01
금
02
토
03
일
04
월
05
화
06
수
07
목
08
금
09
토
10
일
11
월
12
화
13
수
14
목
15
금
16
토
17
일
18
월
19
화
20
수
21
목
22
금
23
토
24
일
25
월
26
화
27
수
28
목
29
금
30
토
31
오전
오후
진료일정 06 月
날짜
일
01
월
02
화
03
수
04
목
05
금
06
토
07
일
08
월
09
화
10
수
11
목
12
금
13
토
14
일
15
월
16
화
17
수
18
목
19
금
20
토
21
일
22
월
23
화
24
수
25
목
26
금
27
토
28
일
29
월
30
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2008.02 서울대학교 의학과 박사
2001.02 서울대학교 의학과 석사
1996.02 서울대학교 의학과 학사

경력

경력
2015.03 ~현재 삼성서울병원, 성균관대학교 의과대학/교수
2005.04 ~ 2015.02 서울대학교병원, 서울대학교 의과대학/조교수, 부교수
2009.07 ~ 2011.01 Dana-Farber Cancer Institute, Boston (Harvard Medical school, Broad Institute)
2004.04 ~ 2005.03 삼성서울병원/전임강사
2002.03 ~ 2004.04 삼성서울병원/전임의
2001.05 ~ 2002.02 서울대학교병원/전임의

학회활동

학회활동
2013.01 ~ 현재 대한유전체학회/홍보위원장(역임), 2014동계학술위원(역임), 2015동계기획위원(역임)
2012.01 ~ 현재 생화학분자생물학회(KSBMB)/2013정기학술위원(역임)
2011.01 ~ 현재 대한신경종양학회/감사, 보험및대외협력위원장(역임), 등록위원장(역임), 다학제소위원장(역임), PRC위원, 다학제위원회 등록책임위원
2011.01 ~ 현재 신경종양학회(SNO)/회원
2010.01 ~ 현재 대한두경부종양학회/편집위원(역임)
2008.01 ~ 현재 국제폐암학회(IASLC)/회원
2007.01 ~ 현재 대한폐암학회/학술위원(역임), 기획위원(역임)
2007.01 ~ 현재 미국암연구학회(AACR)/회원
2005.01 ~ 현재 대한종양내과학회/학술위원장, 다학제위원장(역임), 교육위원(역임), 편집위원(역임), 학술위원(역임), 기획위원(역임)
2003.01 ~ 현재 미국임상암학회(ASCO)/회원
2001.01 ~ 현재 대한내과학회/혈액종양내과분과위원(역임), 학술위원(역임)
2001.01 ~ 현재 대한암학회/이사
2001.01 ~ 현재 대한항암요법연구회/폐암분과위원, 두경부암분과위원, 비뇨기암분과위원(역임), PRC위원(역임)
논문
  • J THORAC ONCOL 2025 10.1016/j.jtho.2024.10.003 The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population Bak, M; Park, H; Lee, SH; Lee, N; Ahn, MJ; Ahn, JS; Jung, HA; Park, S; Cho, J; Kim, J; Park, SJ; Chang, SA; Lee, SC; Park, SW; Kim, EK
    View PubMed
  • SCI REP-UK 2025 10.1038/s41598-024-81704-4 Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer Shin, JE; Jung, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Shim, BY
    View PubMed
  • ANN ONCOL 2025 10.1016/j.annonc.2024.10.011 Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR- mutated lung cancer?' by T. Nishimura and H. Fujimoto Felip, E; Cho, BC; Nguyen, D; Curtin, JC; Sethi, S; Bauml, JM; Lee, S
    View PubMed
  • ONCOLOGY-BASEL 2024 10.1159/000543281 Adjuvant Sequential Chemotherapy for Salivary Duct Carcinomas: A Retrospective Comparative Analysis Kim, Y; Choi, N; Kim, EH; Chung, MK; Son, YI; Oh, D; Ahn, YC; Lee, SH; Jung, HA; Park, S; Kim, J; Jeong, HS; Ahn, MJ
    View PubMed
  • ESMO OPEN 2024 10.1016/j.esmoop.2024.103996 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer Lee, SH; Menis, J; Kim, TM; Kim, HR; Zhou, C; Kurniawati, SA; Prabhash, K; Hayashi, H; Lee, DDW; Imasa, MS; Teh, YL; Yang, JCH; Reungwetwattana, T; Sriuranpong, V; Wu, CE; Ang, Y; Sabando, M; Thiagarajan, M; Mizugaki, H; Noronha, V; Yulianti, M; Zhang, L; Smyth, E; Yoshino, T; Park, JO; Pentheroudakis, G; Park, S; Peters, S; Ahn, JB; Popat, S
    View PubMed
  • CANCER IMMUNOL RES 2024 10.1158/2326-6066.CIR-24-0071 Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Koh, J; Lee, D; Kim, S; Song, SG; Han, B; Jeong, H; Kim, YA; Keam, B; Lee, SH; Kim, K; Jeon, YK; Chung, DH
    View PubMed
  • ESMO OPEN 2024 10.1016/j.esmoop.2024.103961 Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma Hong, MH; Park, S; Vo, T; Cho, J; Jung, HA; Lee, SH; Kim, SH; Zhou, H; Chirovsky, D; Koh, YW; Yoon, SO; Webber, AL; Gumuscu, B; Cho, BC; Ahn, MJ
    View PubMed
  • DRUG RESIST UPDATE 2024 10.1016/j.drup.2024.101159 Comprehensive metabolomic analysis identifies key biomarkers and modulators of immunotherapy response in NSCLC patients Lee, SH; Kim, S; Lee, J; Kim, Y; Joo, Y; Heo, JY; Lee, H; Lee, C; Hwang, GS; Park, H
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.1278 Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAF V600E-Mutated Thyroid Cancer Jeon, Y; Park, S; Lee, SH; Kim, TH; Kim, SW; Ahn, MJ; Jung, HA; Chung, JH
    View PubMed
  • CANCER IMMUNOL IMMUN 2024 10.1007/s00262-024-03852-w Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer Kim, HI; Kim, WG; Kim, M; Ko, NG; Jin, M; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Jeon, MJ; Kim, TY; Kim, WB; Kim, SW; Lee, DH; Jang, SJ; Kim, SW; Chung, JH; Kim, TH; Lee, SH
    View PubMed
  • J CLIN ONCOL 2024 10.1200/JCO.24.01001 Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study Leighl, NB; Akamatsu, H; Lim, SM; Cheng, Y; Minchom, AR; Marmarelis, ME; Sanborn, RE; Yang, JCH; Liu, BG; John, T; Massutí, B; Spira, AI; Lee, SH; Wang, JL; Li, J; Liu, CG; Novello, S; Kondo, M; Tamiya, M; Korbenfeld, E; Moskovitz, M; Han, JY; Alexander, M; Joshi, R; Felip, E; Voon, PJ; Danchaivijitr, P; Hsu, PC; Cruz, FJSM; Wehler, T; Greillier, L; Teixeira, E; Nguyen, D; Sabari, JK; Qin, AE; Kowalski, D; Sendur, MAN; Xie, JH; Ghosh, D; Alhadab, A; Haddish-Berhane, N; Clemens, PL; Lorenzini, P; Verheijen, RB; Gamil, M; Bauml, JM; Baig, M; Passaro, A
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2024.084 Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial Shin, J; Park, S; Kim, KH; Shin, EC; Jung, HA; Cho, JH; Sun, JM; Lee, SH; Choi, YS; Ahn, JS; Kim, J; Park, K; Shim, YM; Kim, HK; Noh, JM; Ahn, YC; Pyo, H; Ahn, MJ
    View PubMed
  • ESMO OPEN 2024 10.1016/j.esmoop.2024.103709 Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05 Kim, TY; Kim, SY; Kim, JH; Jung, HA; Choi, YJ; Hwang, IG; Cha, Y; Lee, GW; Lee, YG; Kim, TM; Lee, SH; Lee, S; Yun, H; Choi, YL; Yoon, S; Han, SW; Kim, TW; Zang, DY; Kang, JH
    View PubMed
  • FRONT ONCOL 2024 10.3389/fonc.2024.1463341 Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer Kim, YG; Lee, B; Ha, C; Lee, C; Jung, HA; Sun, JM; Lee, SH; Ahn, MJ; Choi, YL; Park, S; Kim, JW
    View PubMed
  • EUR J CANCER 2024 10.1016/j.ejca.2024.114204 Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC Hochmair, MJ; Vermaelen, K; Mountzios, G; Carcereny, E; Dooms, C; Lee, SH; Morocz, E; Kato, T; Ciuleanu, TE; Dy, GK; Parente, B; O'Byrne, KJ; Chu, QS; De Castro, G Jr; Girard, N; Snyder, W; Tran, Q; Kormany, W; Houk, B; Mehta, B; Curioni-Fontecedro, A
    View PubMed
  • SCI REP-UK 2024 10.1038/s41598-024-72108-5 Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma Lee, K; Cha, HH; Kim, J; Jang, Y; Son, Y; Joe, CY; Kim, J; Kim, J; Lee, SH; Lee, SHY
    View PubMed
  • ANN ONCOL 2024 10.1016/j.annonc.2024.05.541 Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA Felip, E; Cho, BC; Gutierrez, ; Alip, A; Besse, B; Lu, S; Spira, AI; Girard, N; Califano, R; Gadgeel, SM; Yang, JCH; Yamamoto, S; Azuma, K; Kim, YJ; Lee, KH; Danchaivijitr, P; Ferreira, CG; Cheng, Y; Sendur, MAN; Chang, GC; Wang, CC; Prabhash, K; Shinno, Y; Stroyakovskiy, D; Paz-Ares, L; Rodriguez-Cid, JR; Martin, C; Campelo, MRG; Hayashi, H; Nguyen, D; Tomasini, P; Gottfried, M; Dooms, C; Passaro, A; Schuler, M; Gelatti, ACZ; Owen, S; Perdrizet, K; Ou, SHI; Curtin, JC; Zhang, J; Gormley, M; Sun, T; Panchal, A; Ennis, M; Fennema, E; Bauml, JM; Daksh, M; Sethi, S; Lee, SH
    View PubMed
  • J CLIN ONCOL 2024 10.1200/JCO.24.00720 Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial Camidge, DR; Bar, J; Horinouchi, H; Goldman, J; Moiseenko, F; Filippova, E; Cicin, I; Ciuleanu, T; Daaboul, N; Liu, CL; Bradbury, P; Moskovitz, M; Katgi, N; Tomasini, P; Zer, A; Girard, N; Cuppens, K; Han, JY; Wu, SY; Baijal, S; Mansfield, AS; Kuo, CH; Nishino, K; Lee, SH; Planchard, D; Baik, C; Li, MR; Ansell, P; Xia, S; Bolotin, E; Looman, J; Ratajczak, C; Lu, S
    View PubMed
  • PLOS ONE 2024 10.1371/journal.pone.0310079 Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib Kim, T; Choe, J; Shin, SH; Jeong, BH; Lee, KYJ; Kim, H; Lee, SH; Um, SW
    View PubMed
  • LANCET 2024 10.1016/S0140-6736(24)01756-2 Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial Spicer, JD; Garassino, MC; Wakelee, H; Liberman, M; Kato, T; Tsuboi, M; Lee, SH; Chen, KN; Dooms, C; Majem, M; Eigendorff, E; Martinengo, GL; Bylicki, O; Rodriguez-Abreu, D; Chaft, JE; Novello, S; Yang, J; Arunachalam, A; Keller, SM; Samkari, A; Gao, SG
    View PubMed
  • J CLIN ONCOL 2024 10.1200/JCO.24.00708 Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM) Park, S; Baldry, R; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Kim, YJ; Lee, Y; Kim, DW; Kim, SW; Lee, KH; Lee, WJ; Choi, JW; Chong, K; Lee, JI; Gwon, SH; Son, NH; Ahn, MJ
    View PubMed
  • GASTROINTEST ENDOSC 2024 Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinical application in pancreatic ductal adenocarcinoma (with video) Kim, H; Jang, J; Choi, JH; Song, JH; Lee, SH; Park, JP; Ryoo, SK; Lee, EM; Jeong, HO; Kim, S; Lee, SH; Lee, KH; Lee, KT; Kim, KM; Jang, KT; Lee, H; Lee, S; Lee, JK; Park, JK
    View PubMed
  • CANCER RES 2024 10.1158/0008-5472.CAN-23-2627 CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer Boumelha, J; de Castro, A; Bah, N; Cha, HG; Trecesson, SDC; Rana, S; Tomaschko, M; Anastasiou, P; Mugarza, E; Moore, C; Goldstone, R; East, P; Litchfield, K; Lee, SH; Molina-Arcas, M; Downward, J
    View PubMed
  • NEW ENGL J MED 2024 10.1056/NEJMoa2403614 Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC Cho, BC; Lu, S; Felip, E; Spira, AI; Girard, N; Lee, JS; Lee, SH; Ostapenko, Y; Danchaivijitr, P; Liu, BG; Alip, A; Korbenfeld, E; Dias, JM; Besse, B; Lee, KH; Xiong, HL; How, SH; Cheng, Y; Chang, GC; Yoshioka, H; Yang, JCH; Thomas, M; Nguyen, D; Ou, SHI; Mukhedkar, S; Prabhash, K; D'Arcangelo, M; Alatorre-Alexander, J; Limon, JCV; Alves, S; Stroyakovskiy, D; Peregudova, M; Sendur, MAN; Yazici, O; Califano, R; Calderon, VG; de Marinis, F; Passaro, A; Kim, SW; Gadgeel, SM; Xie, JH; Sun, T; Martinez, M; Ennis, M; Fennema, E; Daksh, M; Millington, D; Leconte, I; Iwasawa, R; Lorenzini, P; Baig, M; Shah, SJ; Bauml, JM; Shreeve, SM; Sethi, S; Knoblauch, RE; Hayashi, H
    View PubMed
  • NAT CANCER 2024 10.1038/s43018-024-00772-7 LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features Chang, TG; Cao, YY; Sfreddo, HJ; Dhruba, SR; Lee, SH; Valero, C; Yoo, SK; Chowell, D; Morris, LGT; Ruppin, E
    View PubMed
  • TRANSL CANCER RES 2024 10.21037/tcr-23-2188 Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer Jung, YJ; Ahn, J; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, SY; Jung, HA
    View PubMed
  • NAT COMMUN 2024 10.1038/s41467-024-48310-4 Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types Kang, J; Lee, JH; Cha, H; An, J; Kwon, J; Lee, S; Kim, S; Baykan, MY; Kim, SY; An, D; Kwon, AY; An, HJ; Lee, SH; Choi, JK; Park, JE
    View PubMed
  • MOL CANCER 2024 10.1186/s12943-024-02003-0 Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications Park, JK; Jeong, HO; Kim, H; Choi, JH; Lee, EM; Kim, S; Jang, J; Choi, DWY; Lee, SH; Kim, KM; Jang, KT; Lee, KH; Lee, KT; Lee, MW; Lee, JK; Lee, SM
    View PubMed
  • BMC CANCER 2024 10.1186/s12885-024-12338-y Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09 Kim, SY; Kim, JH; Kim, TY; Park, SR; Yoon, S; Lee, S; Lee, SH; Kim, TM; Han, SW; Kim, HR; Yun, H; Lee, S; Kim, J; Choi, YL; Choi, KS; Chae, H; Ryu, H; Lee, GW; Zang, DY; Ahn, JB
    View PubMed
  • BRIT J CANCER 2024 10.1038/s41416-024-02698-4 Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer Jeong, H; Koh, J; Kim, S; Song, SG; Lee, SH; Jeon, Y; Lee, CH; Keam, B; Lee, SH; Chung, DH; Jeon, YK
    View PubMed
  • J CLIN ONCOL 2024 10.1200/JCO.23.01017 Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722 Mok, T; Nakagawa, K; Park, K; Ohe, Y; Girard, N; Kim, HR; Wu, YL; Gainor, J; Lee, SH; Chiu, CH; Kim, SW; Yang, CT; Wu, CL; Wu, L; Lin, MC; Samol, J; Ichikado, K; Wang, MZ; Zhang, XQ; Sylvester, J; Li, SN; Forslund, A; Yang, JCH
    View PubMed
  • J CLIN ONCOL 2024 10.1200/JCO.23.01891 Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) Park, S; Kim, TM; Han, JY; Lee, GW; Shim, BY; Lee, YG; Kim, SW; Kim, IH; Lee, S; Kim, YJ; Park, JH; Park, SG; Lee, KH; Kang, EJ; Kim, JW; Shin, SH; Ock, CY; Nam, BH; Lee, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • EBIOMEDICINE 2024 10.1016/j.ebiom.2024.105062 Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer Park, S; Hong, TH; Hwang, S; Heeke, S; Gay, CM; Kim, J; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Cho, JH; Choi, YS; Kim, J; Shim, YM; Kim, HK; Byers, LA; Heymach, JV; Choi, YL; Lee, SH; Park, K
    View PubMed
  • LUNG CANCER 2024 10.1016/j.lungcan.2024.107536 Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis Jung, HA; Park, B; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • JCO PRECIS ONCOL 2024 10.1200/PO.23.00556 Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer Kim, H; Kim, S; Choi, S; Park, C; Park, S; Pereira, S; Ma, MN; Yoo, D; Paeng, K; Jung, WKY; Park, S; Ock, CY; Lee, SH; Choi, YL; Chung, JH
    View PubMed
  • TRANSL LUNG CANCER R 2024 10.21037/tlcr-23-479 Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses Park, S; Kang, JK; Lee, N; Lee, SH; Kim, HP; Kim, SY; Kim, TY; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • J IMMUNOTHER CANCER 2024 10.1136/jitc-2023-008339 Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types Shen, JN; Choi, YL; Lee, T; Kim, H; Chae, YK; Dulken, B; Bogdan, S; Huang, M; Fisher, GA; Park, S; Lee, SH; Hwang, JE; Chung, JH; Kim, L; Song, H; Pereira, S; Shin, S; Lim, Y; Ahn, CH; Kim, S; Oum, C; Kim, S; Park, G; Song, S; Jung, W; Kim, S; Bang, YJ; Mok, TSK; Ali, SM; Ock, CY
    View PubMed
  • CANCER-AM CANCER SOC 2024 10.1002/cncr.35175 Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B Hong, J; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Sinn, DH; Ahn, MJ
    View PubMed
  • ANN ONCOL 2024 10.1016/j.annonc.2023.10.117 Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study Passaro, A; Wang, J; Wang, Y; Lee, SH; Melosky, B; Shih, JY; Wang, J; Azuma, K; Juan-Vidal, O; Cobo, M; Felip, E; Girard, N; Cortot, AB; Califano, R; Cappuzzo, F; Owen, S; Popat, S; Tan, JL; Salinas, J; Tomasini, P; Gentzler, RD; William, WN Jr; Reckamp, KL; Takahashi, T; Ganguly, S; Kowalski, DM; Bearz, A; MacKean, M; Barala, P; Bourla, AB; Girvin, A; Greger, J; Millington, D; Withelder, M; Xie, J; Sun, T; Shah, S; Diorio, B; Knoblauch, RE; Bauml, JM; Campelo, RG; Cho, BC
    View PubMed
  • HISTOPATHOLOGY 2024 10.1111/his.15146 PD-L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC grading system Hwang, S; Hong, TH; Kim, HK; Cho, J; Lee, G; Choi, S; Park, S; Lee, SH; Lee, Y; Jeon, YJ; Lee, J; Park, SY; Cho, JH; Choi, YS; Kim, J; Zo, JI; Shim, YM; Choi, YL
    View PubMed
  • ANN ONCOL 2024 10.1016/j.annonc.2023.10.790 VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC Hochmair, MJ; Vermaelen, K; Mountzios, G; Carcereny, E; Dooms, C; Lee, SH; Morocz, EM; Kato, T; Ciuleanu, TE; Dy, G; Parente, MBMCS; O'Byrne, KJ; Chu, QSC; De Castro, G Jr; Girard, N; Snyder, W; Tran, Q; Kormany, W; Houk, B; Curioni-Fontecedro, A
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.461 First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALKRearrangement: Real-World Data Jeon, Y; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • SCI REP-UK 2023 10.1038/s41598-023-49639-4 Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer Kim, K; Kim, H; Shin, I; Noh, SJ; Kim, JY; Suh, KJ; Kim, YN; Lee, JY; Cho, DY; Kim, SH; Kim, JH; Lee, SH; Choi, JK
    View PubMed
  • GENOME MED 2023 10.1186/s13073-023-01252-w Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes Song, S; Koh, Y; Kim, S; Lee, SM; Kim, HU; Ko, JM; Lee, SH; Yoon, SS; Park, S
    View PubMed
  • ESMO OPEN 2023 10.1016/j.esmoop.2023.102068 Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-643 Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC) Choi, DH; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH
    View PubMed
  • EXP MOL MED 2023 10.1038/s12276-023-01119-5 Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection Kim, SY; Jeong, S; Lee, WK; Jeon, Y; Kim, YJ; Park, S; Lee, DG; Go, D; Song, SH; Lee, SH; Woo, HG; Yoon, JK; Park, YS; Kim, YT; Lee, SH; Kim, KH; Lim, Y; Kim, JS; Kim, HP; Bang, D; Kim, TY
    View PubMed
  • CANCERS 2023 10.3390/cancers15225450 Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations Jun, S; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, J; Jung, HA
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2023.403 Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement Jeon, Y; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2023.502 Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Kim, H; Park, S; Jung, HA; Lee, SH; Park, K; Ahn, YC; Oh, D; Ahn, MJ
    View PubMed
  • J TRANSL MED 2023 10.1186/s12967-023-04549-x Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma Koh, Y; Kim, H; Joo, SY; Song, SL; Choi, YH; Kim, HR; Moon, B; Byun, J; Hong, JS; Shin, DY; Park, S; Lee, KH; Lee, KT; Lee, JK; Park, D; Lee, SH; Jang, JY; Lee, H; Kim, JA; Yoon, SS; Park, JK
    View PubMed
  • J IMMUNOTHER CANCER 2023 10.1136/jitc-2023-007310 Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer Naqash, AR; Mccallen, JD; Mi, E; Iivanainen, S; Marie, MA; Gramenitskaya, D; Clark, J; Koivunen, JP; Macherla, S; Jonnalagadda, S; Polsani, S; Jiwani, RA; Hafiz, M; Muzaffar, M; Brunetti, L; Stroud, CRG; Walker, PR; Wang, K; Chung, YM; Ruppin, E; Lee, SH; Yang, L; Pinato, DJ; Lee, JS; Cortellini, A
    View PubMed
  • CANCER-AM CANCER SOC 2023 10.1002/cncr.35059 Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer Park, S; Kim, YJ; Min, YJ; Mortimer, PGS; Kim, HJ; Smith, SA; Dean, E; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
    View PubMed
  • CANCERS 2023 10.3390/cancers15204999 A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study) Ang, YLE; Zhao, XT; Reungwetwattana, T; Cho, BC; Liao, BC; Yeung, R; Loong, HH; Kim, DW; Yang, JCH; Lim, SM; Ahn, MJ; Lee, SH; Suwatanapongched, T; Kongchauy, K; Ou, QX; Yu, RY; Tai, BC; Goh, BC; Mok, TSK; Soo, RA
    View PubMed
  • SCI REP-UK 2023 10.1038/s41598-023-45296-9 Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients Lee, H; Seo, S; Won, S; Park, WY; Choi, JY; Lee, KH; Lee, SH; Moon, SH
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.05.027 Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Ku, BM; Kim, YJ; Park, S; Sun, JM; Lee, SH; Ahn, JS; Cho, JH; Kim, HK; Choi, YS; Choi, YL; Shin, SH; Jeong, BH; Um, SW; Kim, H; Kim, K; Ahn, MJ; Kim, J
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.05.023 Comment on Leveraging NGS Data to Refine Immunotherapy Response Prediction in NSCLC: PD-L1 Copy Number, Tumor Mutation Burden, and Beyond Hong, TH; Bang, YH; Joe, C; Choi, YL; Lee, SH
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-160 Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.6213 A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Choi, SW; Jung, HA; Cho, HJ; Kim, TM; Park, CK; Nam, D; Lee, SH
    View PubMed
  • NEW ENGL J MED 2023 10.1056/NEJMoa2302983 Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer Wakelee, H; Liberman, M; Kato, T; Tsuboi, M; Lee, SH; Gao, SG; Chen, KN; Dooms, C; Majem, M; Eigendorff, E; Martinengo, GL; Bylicki, O; Rodriguez-Abreu, D; Chaft, JE; Novello, S; Yang, J; Keller, SM; Samkari, A; Spicer, JD
    View PubMed
  • J CLIN ONCOL 2023 10.1200/JCO.2023.41.17_suppl.LBA100 KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC Wakelee, HA; Liberman, M; Kato, T; Tsuboi, M; Lee, SH; He, J; Gao, SG; Chen, KN; Dooms, CA; Majem, M; Eigendorff, E; Martinengo, GL; Bylicki, O; Rodriguez-Abreu, D; Chaft, JE; Novello, S; Yang, J; Keller, SM; Samkari, A; Spicer, J
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.03.024 Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC Hong, TH; Bang, YH; Joe, CY; Hwang, S; Lee, B; Lee, N; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Lee, SH
    View PubMed
  • CANCER-AM CANCER SOC 2023 10.1002/cncr.34892 A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas Lee, J; Park, S; Jung, HA; Lee, SH; Seo, S; Kim, SB; Kim, JW; Lee, KW; Kang, EJ; Kim, JW; Choi, YJ; Shim, BY; An, HJ; Park, LC; Shin, SH; Kim, JJ; Oh, SY; Kim, MK; Ahn, MJ
    View PubMed
  • MODERN PATHOL 2023 10.1016/j.modpat.2023.100184 Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance Hwang, S; Hong, TH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Han, J; Ahn, YC; Pyo, H; Noh, JM; Lee, HY; Kim, HJ; Park, S; Ahn, MJ; Park, K; Lee, SH; Choi, YL; Kim, J
    View PubMed
  • ADV SCI 2023 10.1002/advs.202204378 Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells Lee, SH; Kim, Y; Jeon, BN; Kim, G; Sohn, J; Yoon, Y; Kim, S; Kim, Y; Kim, H; Cha, HG; Lee, NE; Yang, HYS; Chung, JY; Jeong, AR; Kim, YY; Kim, SG; Seo, Y; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, H; Yoon, KW
    View PubMed
  • NATURE 2023 10.1038/s41586-023-05874-3 Lung adenocarcinoma promotion by air pollutants Hill, W; Lim, EL; Weeden, CE; Lee, C; Augustine, M; Chen, K; Kuan, FC; Marongiu, F; Evans, EJ ; Moore, DA; Rodrigues, FS; Pich, O; Bakker, B; Cha, HG; Myers, R; van Maldegem, F; Boumelha, J; Veeriah, S; Rowan, A; Naceur-Lombardelli, C; Karasaki, T; Sivakumar, M; De, S; Caswell, DR; Nagano, A; Black, JRM; Martínez-Ruiz, C; Ryu, MH; Huff, RD; Li, S; Favé, MJ; Magness, A; Suárez-Bonnet, A; Priestnall, SL; Lüchtenborg, M; Lavelle, K; Pethick, J; Hardy, S; McRonald, FE; Lin, MH; Troccoli, CI; Ghosh, M; Miller, YE; Merrick, DT; Keith, RL; Al Bakir, M; Bailey, C; Hill, MS; Saal, LH; Chen, Y; George, AM; Abbosh, C; Kanu, N; Lee, SH; McGranahan, N; Berg, CD; Sasieni, P; Houlston, R; Turnbull, C; Lam, S; Awadalla, P; Grönroos, E; Downward, J; Jacks, T; Carlsten, C; Malanchi, I; Hackshaw, A; Litchfield, K; Lester, JF; DeGregori, J; Jamal-Hanjani, M; Swanton, C
    View PubMed
  • NATURE 2023 10.1038/s41586-023-05771-9 Antibodies against endogenous retroviruses promote lung cancer immunotherapy Ng, KW; Boumelha, J; Enfield, KSS; Almagro, J; Cha, HG; Pich, O; Karasaki, T; Moore, DA; Salgado, R; Sivakumar, M; Young, G; Molina-Arcas, M; Trecesson, SD; Anastasiou, P; Fendler, A; Au, LW; Shepherd, STC; Martinez-Ruiz, C; Puttick, C; Black, JRM; Watkins, TBK; Kim, H; Shim, S; Faulkner, N; Attig, J; Veeriah, S; Magno, N; Ward, S; Frankell, AM; Al Bakir, M; Lim, EL; Hill, MS; Wilson, GA; Cook, DE; Birkbak, NJ; Behrens, A; Yousaf, N; Popat, S; Hackshaw, A; TRACERx Consortium; CAPTURE Consortium; Hiley, CT; Litchfield, K; McGranahan, N; Jamal-Hanjani, M; Larkin, J; Lee, SH; Turajlic, S; Swanton, C; Downward, J; Kassiotis, G
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.388 EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1344 The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.910 Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma Lee, MS; An, S; Song, JY; Sung, M; Jung, K; Chang, ES; Choi, J; Oh, DY; Jeon, YK; Yang, H; Lakshmi, C; Park, S; Han, J; Lee, SH; Choi, YL
    View PubMed
  • JAMA NETW OPEN 2023 10.1001/jamanetworkopen.2023.2002 Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020 Chi, SA; Yu, H; Choi, YL; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Choi, DH; Kim, K; Jung, HA; Park, K
    View PubMed
  • J IMMUNOTHER CANCER 2023 10.1136/jitc-2022-005509 Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment Kim, H; Park, S; Han, KY; Lee, N; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH; Park, WY
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2022.10.008 A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21) Jung, HA; Kim, M; Kim, HS; Kim, JH; Choi, YH; Cho, J; Park, JH; Park, KU; Ku, BM; Park, S; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2021.1603 Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI Kim, HR; Jo, H; Kim, H; Hong, J; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • NAT GENET 2023 10.1038/s41588-022-01273-y MHC II immunogenicity shapes the neoepitope landscape in human tumors Kim, JY; Cha, HG; Kim, K; Sung, CH; An, JHY; Bang, H; Kim, H; Yang, JO; Chang, SH; Shin, I; Noh, SJ; Shin, I; Cho, DY; Lee, SH; Choi, JK
    View PubMed
  • FRONT IMMUNOL 2023 10.3389/fimmu.2022.1038089 Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors Park, C; Jeong, DY; Choi, Y; Oh, YJ; Kim, J; Ryu, J; Paeng, K; Lee, SH; Ock, CY; Lee, HY
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.5530 Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers Kim, JE; Kim, H; Kim, B; Chung, HG; Chung, HH; Kim, KM; Kim, SH; Jeong, WK; Kim, YK; Min, JH; Heo, JS; Han, IW; Shin, SH; Park, HC; Yu, JI; Park, JO; Kim, ST; Hong, JY; Lee, SH; Lee, KH; Lee, JK; Lee, KT; Jang, KT; Park, JK
    View PubMed
  • INT J RADIAT ONCOL 2023 10.1016/j.ijrobp.2022.07.018 Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Kim, CG; Yoon, HI; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Shin, EC; Ahn, MJ
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.5460 Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma Park, S; Cha, H; Kim, HS; Lee, B; Kim, S; Kim, TM; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
    View PubMed
  • CANCER RES 2022 10.1158/0008-5472.CAN-22-0432 High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities Roh, W; Geffen, Y; Cha, H; Miller, M; Anand, S; Kim, J; Heiman, DI; Gainor, JF; Laird, PW; Cherniack, AD; Ock, CY; Lee, SH; Getz, G
    View PubMed
  • PLOS ONE 2022 10.1371/journal.pone.0274830 Prognostic value of FOXP3+regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma Hur, JY; Ku, BM; Park, S; Jung, HA; Lee, SH; Ahn, MJ
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-22-0879 Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC Jung, HA; Lim, J; Choi, YL; Lee, SH; Joung, JG; Jeon, YJ; Choi, JW; Shin, S; Cho, JH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Han, JH; Park, WY; Kim, J; Park, K
    View PubMed
  • ISCIENCE 2022 10.1016/j.isci.2022.105358 Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma Jeong, HO; Lee, H; Kim, H; Jang, J; Kim, S; Hwang, T; Choi, DWY; Kim, HS; Lee, N; Lee, YM; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SM; Lee, SH
    View PubMed
  • FRONT MED-LAUSANNE 2022 10.3389/fmed.2022.896494 Metabolic parameters on baseline F-18-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma Kwon, HR; Cho, JH; Park, S; Lee, SH; Ahn, MJ; Choi, JY; Lee, KH; Jung, HA; Moon, SH
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2022.07.004 TCF1(+)PD-1(+) tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer Koh, J; Kim, S; Woo, YD; Song, SG; Yim, J; Han, BGY; Lim, S; Ahn, HK; Mun, S; Kim, JS; Keam, B; Kim, YA; Lee, SH; Jeon, YK; Chung, DH
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.1019 A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer Kim, HR; Lee, SJ; Park, S; Jung, HA; Lee, SH; Jeong, HS; Chung, MK; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2022 10.1016/j.jtho.2022.04.001 Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial Lee, J; Koh, J; Kim, HK; Hong, S; Kim, K; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.02010 Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer Park, S; Ock, CY; Kim, H; Pereira, S; Park, S; Ma, M; Choi, S; Kim, S; Shin, S; Aum, BJ; Paeng, K; Yoo, D; Cha, H; Park, S; Suh, KJ; Jung, HA; Kim, SH; Kim, YJ; Sun, JM; Chung, JH; Ahn, JS; Ahn, MJ; Lee, JS; Park, K; Song, SY; Bang, YJ; Choi, YL; Mok, TS; Lee, SH
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-3646 Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study Jung, HA; Park, S; Choi, YL; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2022.04.011 Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response Choi, S; Cho, SI; Ma, M; Park, S; Pereira, S; Aum, BJ; Shin, S; Paeng, K; Yoo, D; Jung, W; Ock, CY; Lee, SH; Choi, YL; Chung, JH; Mok, TS; Kim, H; Kim, S
    View PubMed
  • INT J RADIAT ONCOL 2022 10.1016/j.ijrobp.2022.02.003 Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Yoon, HI; Moon, H; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Ahn, MJ; Shin, EC
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.4663 Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors Kwon, M; Ku, BM; Olsen, S; Park, S; Lefterova, M; Odegaard, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2022.03.034 Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer Park, S; Noh, JM; Choi, YL; Chi, SA; Kim, K; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • TRANSL ONCOL 2022 10.1016/j.tranon.2021.101321 Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma Kim, H; Heo, CM; Oh, J; Chung, HH; Lee, EM; Park, J; Lee, SH; Lee, KH; Lee, KT; Lee, JK; Cho, YK; Park, JK
    View PubMed
  • ESMO OPEN 2022 10.1016/j.esmoop.2021.100341 Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia Cao, Y; Qin, S; Luo, S; Li, Z; Cheng, Y; Fan, Y; Sun, Y; Yin, X; Yuan, X; Li, W; Liu, T; Hsu, CH; Lin, X; Kim, SB; Kojima, T; Zhang, J; Lee, SH; Bai, Y; Muro, K; Doi, T; Bai, C; Gu, K; Pan, HM; Bai, L; Yang, JW; Cui, Y; Lu, W; Chen, J
    View PubMed
  • ONCOLOGY-BASEL 2022 10.1159/000516813 Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor Ku, BM; Kim, YJ; Park, D; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Sun, JM
    View PubMed
  • ESMO OPEN 2022 10.1016/j.esmoop.2022.100385 Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study Park, S; Sun, JM; Choi, YL; Oh, D; Kim, HK; Lee, T; Chi, SA; Lee, SH; Choi, YS; Jung, SH; Ahn, MJ; Ahn, YC; Park, K; Shim, YM
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.306 Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CLIN TRANSL MED 2022 10.1002/ctm2.714 Gene essentiality for tumour growth influences neoantigen-directed immunoediting Bang, H; Park, JS; Kim, JY; Sung, C; An, J; Cho, DY; Lee, SH; Shim, SB; Choi, JK; Kim, K
    View PubMed
  • INVEST NEW DRUG 2022 10.1007/s10637-021-01121-6 ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer Ku, BM; Heo, JY; Kim, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J NEURO-ONCOL 2022 10.1007/s11060-021-03930-4 Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma Lee, YP; Jung, HA; Lee, MS; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Lee, JI; Lee, SH
    View PubMed
  • CANCERS 2021 10.3390/cancers13112791 2021 Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy Park1, JK; Kim, H; Son, DS; Kim, NKD; Sung, YK; Cho, M; Lee, C; Noh, DH; Lee, SH; Lee, KT; Lee, JK; Jang, KT; Park, WY; Lee, KH
    View PubMed
  • CELL 2021 10.1016/j.cell.2021.03.030 2021 Synthetic lethality-mediated precision oncology via the tumor transcriptome Lee1, JS; Nair, NU; Dinstag, G; Chapman, L; Chung, YM; Wang, K; Sinha, S; Cha, H; Kim, D; Schperberg, AV; Srinivasan, A; Lazar, V; Rubin, E; Hwang, S; Berger, R; Beker, T; Ronai, ZE; Hannenhalli, S; Gilbert, MR; Kurzrock, R; Lee, SH; Aldape, K; Ruppin, E
    View PubMed
  • CANCER 2021 10.1002/cncr.33571 2021 High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program Park1, S; Olsen, S; Ku, BM; Lee, MS; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ
    View PubMed
  • J KOREAN NEUROSURG SOC 2021 10.3340/jkns.2020.0135 2021 Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery Lee1, MH; Cho, KR; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Lee, JI
    View PubMed
  • CELL 2021 10.1016/j.cell.2021.01.002 2021 Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition Litchfield1, K; Reading, JL; Puttick, C; Thakkar, K; Abbosh, C; Bentham, R; Watkins, TBK; Rosenthal, R; Biswas, D; Rowan, A; Lim, E; Al Bakir, M; Turati, V; Guerra-Assuncao, JA; Conde, L; Furness, AJS; Saini, SK; Hadrup, SR; Herrero, J; Lee, SH; Van Loo, P; Enver, T; Larkin, J; Hellmann, MD; Turajlic, S; Quezada, SA; McGranahan, N; Swanton, C
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-20-1128 2021 Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors Kim1, H; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • EUR J IMMUNOL 2021 10.1002/eji.202048966 2021 Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer Ku1, BM; Kim, Y; Lee, KY; Kim, SY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • NAT MICROBIOL 2021 10.1038/s41564-020-00831-6 2021 Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice Lee1, SH; Cho, SY; Yoon, YM; Park, CH; Sohn, JY; Jeong, JJ; Jeon, BN; Jang, M; An, C; Lee, S; Kim, YY; Kim, G; Kim, S; Kim, Y; Lee, GB; Lee, EJ; Kim, SG; Kim, HS; Kim, YM; Kim, H; Yang, HS; Kim, S; Kim, S; Chung, H; Moon, MH; Nam, MH; Kwon, JY; Won, S; Park, JS; Weinstock, GM; Lee, C; Yoon, KW; Park, H
    View PubMed
  • CANCERS 2021 10.3390/cancers13236050 Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach Song, C; Park, H; Lee, HY; Lee, S; Ahn, JH; Lee, SH
    View PubMed
  • THORAC CANCER 2021 10.1111/1759-7714.14297 Rarest of rare cases within the one thousand faces of atypical carcinoid: Pseudomesotheliomatous manifestation in a pregnant woman Kim, H; Lee, HY; Lee, SH; Lee, IS; Choi, JY; Shim, YM
    View PubMed
  • EPMA J 2021 10.1007/s13167-021-00266-x Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies Park, JG; Choi, BK; Lee, Y; Jang, EJ; Woo, SM; Lee, JH; Kim, KH; Hwang, H; Choi, W; Lee, SH; Yoo, BC
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.09.037 Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience Lee, YP; Jeong, BH; Eun, Y; Kang, CI; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-691 Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment Hwang, S; Hong, TH; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Lee, SH
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-531 Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system Jung, HA; Jeong, O; Chang, DK; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • CANCERS 2021 10.3390/cancers13164077 Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma Choi, Y; Aum, J; Lee, SH; Kim, HK; Kim, J; Shin, S; Jeong, JY; Ock, CY; Lee, HY
    View PubMed
  • NANOMED-NANOTECHNOL 2021 10.1016/j.nano.2021.102415 Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model Koh, J; Kim, S; Lee, SN; Kim, SY; Kim, JE; Lee, KY; Kim, MS; Heo, JY; Park, YM; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Yang, S; Ha, SJ; Lim, YT; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2020 10.1200/JCO.20.01888 2020 Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Kojima1, T; Shah, MIA; Muro, K; Francois, E; Adenis, A; Hsu, CH; Doi, T; Moriwaki, T; Kim, SB; Lee, SH; Bennouna, J; Kato, K; Shen, L; Enzinger, P; Qin, SK; Ferreira, P; Chen, J; Girotto, G; de la Fouchardiere, C; Senellart, H; Al-Rajabi, R; Lordick, F; Wang, RX; Suryawanshi, S; Bhagia, P; Kang, SP; Metges, JP
    View PubMed
  • IMMUNE NETW 2020 10.4110/in.2020.20.e48 2020 Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs Kim1, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • ANN TRANSL MED 2020 10.21037/atm-20-3466 2020 Treatment strategy for papillary renal cell carcinoma type 2 a case series of seven patients treated based on next generation sequencing data Kim1, JY; Jeong, HO; Heo, DS; Keam, B; Moon, KC; Kwak, C; Jang, J; Kim, S; Kim, JI; Lee, S; Lee, SH
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-76130-1 2020 Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer Koh1, J; Hur, JY; Lee, KY; Kim, MS; Heo, JY; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER IMMUNOL IMMUN 2020 10.1007/s00262-020-02796-1 2020 Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy Park1, C; Jeong, K; Park, JH; Jung, S; Bae, JM; Kim, K; Ock, CY; Kim, M; Keam, B; Kim, TM; Jeon, YK; Lee, SH; Lee, JS; Kim, DW; Kang, GH; Chung, DH; Heo, DS
    View PubMed
  • J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 2020 Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status Lee1, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2020.278 2020 EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation Park1, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ
    View PubMed
  • J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199 2020 Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY
    View PubMed
  • BIOLOGY-BASEL 2020 10.3390/biology9100326 2020 Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations? Jung1, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379 2020 The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer Jung1, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.06.017 2020 A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy Park1, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER 2020 10.1002/cncr.33048 2020 Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy Park1, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
    View PubMed
  • LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035 2020 Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer Jung1, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K
    View PubMed
  • ISCIENCE 2020 10.1016/j.isci.2020.101386 2020 Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma Kim1, HK; Joung, JG; Choi, YL; Lee, SH; Park, BJ; Choi, YS; Ryu, D; Nam, JY; Lee, MS; Park, WY; Hwang, S; Cha, H; Kim, HS; Lee, S; Jung, Y; Lee, JE; Doh, J; Paik, S; Kang, JH; Lee, J; Kim, J
    View PubMed
  • LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033 2020 Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study) Jung1, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-70168-x 2020 Metabolic radiogenomics in lung cancer associations between FDG PET image features and oncogenic signaling pathway alterations Kim1, G; Kim, J; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Park, YJ; Choi, JY; Lee, KH; Lee, SH; Moon, SH
    View PubMed
  • J TRANSL MED 2020 10.1186/s12967-020-02473-y 2020 PDX models of human lung squamous cell carcinoma consideration of factors in preclinical and co-clinical applications Jung1, HY; Kim, TH; Lee, JE; Kim, HK; Cho, JH; Choi, YS; Shin, S; Lee, SH; Rhee, H; Lee, HK; Choi, HJ; Jang, HY; Lee, S; Kang, JH; Choi, YA; Lee, S; Lee, J; Choi, YL; Kim, J
    View PubMed
  • BMC CANCER 2020 10.1186/s12885-020-07214-4 2020 Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer real-world data in Korea Kim1, H; Kwon, M; Kim, B; Jung, HA; Sun, JM; Lee, SH; Park, K; Ahn, MJ
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.04.004 2020 HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients Shim1, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
    View PubMed
  • EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 2020 Evaluating entrectinib as a treatment option for non-small cell lung cancer Lee1, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC DIS 2020 10.21037/jtd.2019.08.29 2020 Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • EUR J CANCER 2020 10.1016/j.ejca.2020.03.029 2020 Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma Lee1, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CANCER 2020 10.1002/cncr.32809 2020 Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer Lee1, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • NAT COMMUN 2020 10.1038/s41467-020-16164-1 2020 Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Kim1, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO
    View PubMed
  • CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006 2020 Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests Byeon1, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • IN VIVO 2020 10.21873/invivo.11920 2020 Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping Hur1, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2020 10.1016/j.jtho.2020.01.016 2020 New Approaches to SCLC Therapy: From the Laboratory to the Clinic Poirier1, JT; George, J; Owonikoko, TK; Berns, A; Brambilla, E; Byers, LA; Carbone, D; Chen, HJ; Christensen, CL; Dive, C; Farago, AF; Govindan, R; Hann, C; Hellmann, MD; Horn, L; Johnson, JE; Ju, YS; Kang, SM; Krasnow, M; Lee, J; Lee, SH; Lehman, J; Lok, B; Lovly, C; MacPherson, D; McFadden, D; Minna, J; Oser, M; Park, K; Park, KS; Pommier, Y; Quaranta, V; Ready, N; Sage, J; Scagliotti, G; Sos, ML; Sutherland, KD; Travis, WD; Vakoc, CR; Wait, SJ; Wistuba, I; Wong, KK; Zhang, H; Daigneault, J; Wiens, J; Rudin, CM; Oliver, TG
    View PubMed
  • INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3 2020 Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer Ku1, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J MOL DIAGN 2020 10.1016/j.jmoldx.2019.10.015 2020 Junction Location Identifier (JuLI) Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology Shin1, HT; Kim, NKD; Yun, JW; Lee, B; Kyung, S; Lee, KW; Ryu, D; Kim, J; Bae, JS; Park, D; Choi, YL; Lee, SH; Ahn, MJ; Park, K; Park, WY
    View PubMed
  • J CLIN ONCOL 2020 10.1200/JCO.19.00931 2020 Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) Cho1, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • Cancer Med 2020 10.1002/cam4.2868 2020 PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence Byeon1, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • RESP MED 2020 10.1016/j.rmed.2019.105853 2020 Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors Im1, Y; Lee, J; Kim, SJ; Koh, WJ; Jhun, BW; Lee, SH
    View PubMed
  • BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9 2020 Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors Shin1, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY
    View PubMed
  • Oncoimmunology 2020 10.1080/2162402X.2020.1722023 2020 Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment Kim1, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2019.186 2020 Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea Lee1, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.10.010 2019 In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing Park1, S; Lee, SH; Park, K
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32235 2019 Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease Shin1, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH
    View PubMed
  • EUR J CANCER 2019 10.1016/j.ejca.2019.08.001 2019 Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033 2019 Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Kim1, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014 2019 DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC Park1, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • NAT COMMUN 2019 10.1038/s41467-019-12159-9 2019 DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load Jung1, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK
    View PubMed
  • J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184 2019 Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial Cho1, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024 2019 Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma Park1, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • BMC CANCER 2019 10.1186/s12885-019-6044-z 2019 NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors Phi1, JH; Sun, CH; Lee, SH; Lee, S; Park, I; Choi, SA; Park, SH; Lee, JY; Wang, KC; Kim, SK; Yun, H; Park, CK
    View PubMed
  • ONCOLOGIST 2019 10.1634/theoncologist.2019-0070 2019 A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma Keam1, B; Lee, KW; Lee, SH; Kim, JS; Kim, JH; Wu, HG; Eom, KY; Kim, S; Ahn, SH; Chung, EJ; Kwon, SK; Jeong, WJ; Jung, YH; Kim, JW; Heo, DS
    View PubMed
  • Lancet Respir Med 2019 10.1016/S2213-2600(19)30053-0 2019 Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study Zhou1, CC; Kim, SW; Reungwetwattana, T; Zhou, JY; Zhang, YP; He, JX; Yang, JJ; Cheng, Y; Lee, SH; Bu, LL; Xu, TT; Yang, L; Wang, C; Liu, T; Morcos, PN; Lu, Y; Zhang, L
    View PubMed
  • J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x 2019 Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma Park1, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0 2019 Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma Cho1, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020 2019 Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ
    View PubMed
  • RADIOTHER ONCOL 2019 10.1016/j.radonc.2019.01.005 2019 Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery Cho1, WK; Oh, D; Kim, HK; Ahn, YC; Noh, JM; Shim, YM; Zo, JI; Choi, YS; Sun, JM; Lee, SH; Ahn, MJ; Park, K; Nam, H
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.117 2019 Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib Kim1, Y; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-1449 2019 The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors Kim1, KH; Cho, J; Ku, BM; Koh, J; Sun, JM; Lee, SH; Ahn, JS; Cheon, J; Min, YJ; Park, SH; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012 2019 Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer Lee1, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.324 2019 A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13 Yoo1, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, HG; Ahn, HJ; Lee, HY; Yun, HJ; Kang, JH; Jeong, J; Choi, MY; Jung, SH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.125 2019 EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy Park1, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.151 2019 Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea Byeon1, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2018.10.150 2019 Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC Kim1, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • EUR J NUCL MED MOL I 2019 10.1007/s00259-018-4138-5 2019 Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer Moon1, SH; Kim, J; Joung, JG; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Choi, JY; Lee, KH; Kim, BT; Lee, SH
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.138 2019 Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer Lee1, J; Shim, JH; Park, WY; Kim, HK; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.132 2019 Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients Lee1, SH; Lee, B; Shim, JH; Lee, KW; Md, JWY; Kim, SY; Kim, TY; Kim, YH; Ko, YH; Chung, HC; Yu, CS; Lee, J; Rha, SY; Kim, TW; Jung, KH; Im, SA; Moon, HG; Cho, S; Kang, JH; Kim, J; Kim, SK; Ryu, HS; Ha, SY; Il Kim, J; Chung, YJ; Kim, C; Kim, HL; Park, WY; Noh, DY; Park, K
    View PubMed
  • RADIAT ONCOL 2018 10.1186/s13014-018-1196-6 2018 Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion Kim1, H; Oh, D; Ahn, YC; Park, K; Ahn, MJ; Lee, SH; Sun, JM; Shim, YM; Zo, JI; Choi, YS; Kim, HK; Cho, JH
    View PubMed
  • CLIN GENITOURIN CANC 2018 10.1016/j.clgc.2018.05.011 2018 A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Noneclear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus Park1, I; Lee, SH; Lee, JL
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003 2018 Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial Lim1, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026 2018 Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice Park1, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ
    View PubMed
  • CLIN CANCER RES 2018 10.1158/1078-0432.CCR-17-3492 2018 Integrin beta 3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC Noh1, KW; Sohn, I; Song, JY; Shin, HT; Kim, YJ; Jung, K; Sung, M; Kim, M; An, S; Han, J; Lee, SH; Lee, MS; Choi, YL
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.06.009 2018 Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma Lee1, J; Jung, HA; Kim, Y; Choi, S; Han, J; Choi, YL; Lee, SH; Ahn, JS; Park, K; Sun, JM
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2018.04.038 2018 Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication Lee1, H; Lee, HY; Sun, JM; Lee, SN; Kim, Y; Park, SE; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • Journal of thoracic disease 2018 10.21037/jtd.2018.04.127 2018 The more and the heavier may not always be an answer Pyo1, H; Lee, SH; Kim, J
    View PubMed
  • PLoS One 2018 10.1371/journal.pone.0194730 2018 Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model Ku1, BM; Choi, MK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.01.004 2018 Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy Park1, BJ; Cho, JH; Lee, JH; Shin, S; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Kim, J
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.007 2018 Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer Cho1, JH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.014 2018 KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma Cho1, JH; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • BRIT J CANCER 2018 10.1038/bjc.2017.465 2018 Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07) Sun1, JM; Lee, KH; Kim, BS; Kim, HG; Min, YJ; Yi, SY; Yun, HJ; Jung, SH; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • PLoS One 2018 10.1371/journal.pone.0189766 2018 Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor Park1, S; Ha, S; Lee, SH; Paeng, JC; Keam, B; Kim, TM; Kim, DW; Heo, DS
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.011 2018 Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer Park1, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • Oncoimmunology 2018 10.1080/2162402X.2017.1375642 2018 Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer Kim1, HI; Kim, M; Lee, SH; Park, SY; Kim, YN; Kim, H; Jeon, MJ; Kim, TY; Kim, SW; Kim, WB; Kim, SW; Lee, DH; Park, K; Ahn, MJ; Chung, JH; Shong, YK; Kim, WG; Kim, TH
    View PubMed
  • J THORAC ONCOL 2017 10.1016/j.jtho.2017.09.1954 2017 Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer Sun1, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K
    View PubMed
  • NAT COMMUN 2017 10.1038/s41467-017-01470-y 2017 Prevalence and detection of low-allele-fraction variants in clinical cancer samples Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY
    View PubMed
  • J PATHOL 2017 10.1002/path.4950 2017 Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer Noh1, KW; Lee, MS; Lee, SE; Song, JY; Shin, HT; Kim, YJ; Oh, DY; Jung, K; Sung, M; Kim, M; An, S; Han, J; Shim, YM; Zo, JI; Kim, J; Park, WY; Lee, SH; Choi, YL
    View PubMed
  • CANCER RES TREAT 2017 10.4143/crt.2016.424 2017 Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer Lee1, MY; Ku, BM; Kim, HS; Lee, JY; Lim, SH; Sun, JM; Lee, SH; Park, K; Oh, YL; Hong, M; Jeong, HS; Son, YI; Baek, CH; Ahn, MJ
    View PubMed
  • EXPERT REV MOL DIAGN 2017 10.1080/14737159.2017.1372196 2017 An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer Ku1, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3396-4 2017 Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors Kim1, HK; Heo, MH; Lee, HS; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2017 10.1200/JCO.2016.71.9096 2017 Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas Lee1, JK; Lee, J; Kim, S; Kim, S; Youk, J; Park, S; An, Y; Keam, B; Kim, DW; Heo, DS; Kim, YT; Kim, JS; Kim, SH; Lee, JS; Lee, SH; Park, K; Ku, JL; Jeon, YK; Chung, DH; Park, PJ; Kim, J; Kim, TM; Ju, YS
    View PubMed
  • ONCOTARGET 2017 2017 Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer Ku1, BM; Bae, YH; Koh, J; Sun, JM; Lee, SSH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • SCI REP-UK 2017 10.1038/s41598-017-12557-3 2017 Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma Kim1, S; Kim, JE; Kim, YH; Hwang, T; Kim, SK; Xu, WJ; Shin, JY; Kim, JI; Choi, H; Kim, HC; Cho, HR; Choi, A; Chowdhury, T; Seo, Y; Dho, YS; Kim, JW; Kim, DG; Park, SH; Kim, H; Choi, SH; Park, S; Lee, SH; Park, CK
    View PubMed
  • J MED GENET 2017 10.1136/jmedgenet-2016-104390 2017 Comprehensive somatic genome alterations of urachal carcinoma Lee1, S; Lee, J; Sim, SH; Lee, Y; Moon, KC; Lee, C; Park, WY; Kim, NKD; Lee, SH; Lee, H
    View PubMed
  • BMC Cancer. 2017 May 15;17(1):330. doi: 10.1186/s12885-017-3282-9. 2017 Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma Lee Y11, Park S2, Lee SH3,4, Lee H5.
    View PubMed
  • Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8. 2017 EGFR TKI combination with immunotherapy in non-small cell lung cancer Ahn MJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1.
    View PubMed
  • Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. 2017 Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
    View PubMed
  • Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283. 2017 Osimertinib for the treatment of non-small cell lung cancer Sun JM11, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.
    View PubMed
  • RADIOTHERAPY AND ONCOLOGY, FEB 2017, 122(2):217-223, DOI: 10.1016/j.radonc.2016.09.015 2017 A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer Lee JY1, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K
    View PubMed
  • Ann Oncol. 2017 Feb 1;28(2):292-297. doi: 10.1093/annonc/mdw559. 2017 Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial Lee SH11, Lee JK2, Ahn MJ1, Kim DW2, Sun JM1, Keam B2, Kim TM2, Heo DS2, Ahn JS1, Choi YL3, Min HS4, Jeon YK4, Park K1.
    View PubMed
  • Lancet Respir Med. 2017 Feb;5(2):e10. doi: 10.1016/S2213-2600(17)30010-3. 2017 Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC Lee SH11, Lee JK2.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. 2017 The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
    View PubMed
  • Cancer Res Treat. 2017 Jan;49(1):129-140. doi: 10.4143/crt.2015.466. Epub 2016 May 18. 2017 Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma Cha Y11, Kim YJ2, Lee SH1,3, Kim TM1, Choi SH4, Kim DW1, Park CK5, Kim IH6, Kim JH2, Kim E7, Choi B7, Kim CY8, Kim IA9, Heo DS1.
    View PubMed
  • Cancer Res Treat. 2017 Jan;49(1):193-203. doi: 10.4143/crt.2015.473. Epub 2016 Jun 27. 2017 Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea Kim BS11, Seol HJ2, Nam DH2, Park CK3, Kim IH4, Kim TM5, Kim JH6, Cho YH6, Yoon SM7, Chang JH8, Kang SG8, Kim EH8, Suh CO9, Jung TY10, Lee KH11, Kim CY12, Kim IA13, Hong CK14, Yoo H15, Kim JH16, Kang SH17, Kang MK18, Kim EY19, Kim SH20, Chung DS21, Hwang SC22, Song JH23, Cho SJ24, Lee SI25, Lee YS26, Ahn KJ27, Kim SH28, Lim DH29, Gwak HS30, Lee SH31, Hong YK32.
    View PubMed
  • J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130. 2016 Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision Ahn MJ11, Sun JM2, Lee SH2, Ahn JS2, Park K2.
    View PubMed
  • JOURNAL OF SURGICAL ONCOLOGY, DEC 1 2016, 114(7):888-894, DOI: 10.1002/jso.24412 2016 Prognostic significance of clinical and F-18-FDG PET/CT parameters for post-distant metastasis survival in head and neck squamous cell carcinoma patients Cho JK1, Hyun SH, Choi JY, Choi N, Kim MJ, Lee SH, Baek KH, Jeong HS
    View PubMed
  • Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17. 2016 Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study Lim SH11, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.
    View PubMed
  • Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5. 2016 AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells Ku BM11, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.
    View PubMed
  • Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22. 2016 Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis Byeon S11, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26. 2016 Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria Kim HS11, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14. 2016 A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib Lee JY11, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.
    View PubMed
  • Oncotarget. 2016 Apr 26;7(17):23874-84. doi: 10.18632/oncotarget.8074. 2016 Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers Lee B11,2, Lee T1, Lee SH3,2, Choi YL1,2, Han J1.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):527-36. doi: 10.4143/crt.2015.249. Epub 2015 Sep 15. 2016 Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma Kim HS11, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.
    View PubMed
  • Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543. 2016 The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma Ku BM11, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.
    View PubMed
  • Cancer Biomark. 2016;16(3):425-33. doi: 10.3233/CBM-160581. 2016 Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer Park S11, Park S1, Lee SH1,2, Suh B3, Ock CY1, Keam B1, Kim TM1, Kim DW1, Kim YW1, Heo DS1.
    View PubMed
  • Thyroid. 2016 Mar;26(3):404-13. doi: 10.1089/thy.2015.0316. Epub 2015 Dec 14. 2016 Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma Lee DY11, Won JK2, Lee SH3, Park do J4, Jung KC2, Sung MW5, Wu HG6, Kim KH5, Park YJ4, Hah JH5.
    View PubMed
  • EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652 2016 Pembrolizumab for the treatment of non-small cell lung cancer Lim SH1, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ
    View PubMed
  • Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874. 2016 Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee JY11, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.
    View PubMed
  • BMC Cancer. 2016 Feb 29;16:170. doi: 10.1186/s12885-016-2209-1. 2016 Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis Cha S11, Lee J2, Shin JY3, Kim JY4, Sim SH5, Keam B6,7, Kim TM8,9, Kim DW10,11, Heo DS12,13, Lee SH14,15,16,17, Kim JI18,19,20,21.
    View PubMed
  • Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17. 2016 Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02) Lee JY11, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.
    View PubMed
  • Oncotarget. 2015 Dec 22;6(41):43653-66. doi: 10.18632/oncotarget.6189. 2015 Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas Park CK11, Park I2, Lee S3, Sun CH3, Koh Y4, Park SH5, Kim JE1, Yun H3, Lee SH6.
    View PubMed
  • J Thorac Oncol. 2015 Dec;10(12):1667-9. doi: 10.1097/JTO.0000000000000701. 2015 The MISSION Impossible No, the Journey Should Continue with Better Targeting! Lee SH11, Park K.
    View PubMed
  • J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692. 2015 A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors Kim HS11, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.
    View PubMed
  • Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4. 2015 Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs Lee SJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.
    View PubMed
  • J Neurooncol. 2015 Aug;124(1):101-10. doi: 10.1007/s11060-015-1808-z. Epub 2015 May 31. 2015 Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas Kim BS11, Kim SK, Choi SH, Lee SH, Seol HJ, Nam DH, Lee JI, Park CK, Kong DS.
    View PubMed
  • Oncotarget. 2015 Aug 21;6(24):20266-77. 2015 Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas Kim JE11, Cho HR2, Xu WJ3, Kim JY1, Kim SK4, Kim SK1,5, Park SH6, Kim H2, Lee SH7, Choi SH2, Park S3, Park CK1.
    View PubMed
  • PLoS One. 2015 Jul 22;10(7):e0133371. doi: 10.1371/journal.pone.0133371. eCollection 2015. 2015 Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy Kim M11, Ku JH2, Kwak C2, Kim HH2, Lee E2, Keam B3, Kim TM3, Heo DS3, Lee SH4, Moon KC5.
    View PubMed
  • Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5. 2006 Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Park SH11, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.
    View PubMed
  • J Cell Biochem. 2005 Mar 1;94(4):695-707. 2005 Arsenic trioxide represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60 Han SS11, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S.
    View PubMed
  • Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8. 2005 Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission Lee SH11, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.
    View PubMed
  • Cell Signal. 2005 Jan;17(1):111-9. 2005 Activation of Rafl and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells Park S11, Park CH, Hahm ER, Kim K, Kimler BF, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Lee JH.
    View PubMed
  • Bone Marrow Transplant. 2003 Nov;32(9):889-95. 2003 Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia Park J11, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.
    View PubMed